Tag Archives: Eli Lilly

Op Ed: New Year’s Resolutions for the Drug Industry for 2010

Clearly the drug industry needs New Year’s Resolutions–and to honor them better than the Corporate Integrity Agreements with the government it keeps breaking. How about: “We will stop upgrading anxiety to depression, depression to bipolar disorder and bipolar disorder to ‘treatment resistant depression’ to sell drugs. We will admit that studies are beginning to show that the reason depression is sometimes treatment resistant is because it wasn’t depression to begin with but consumer advertising.”

That British Drug Maker Glaxo’s $1 Billion Paxil Settlements Were Disclosed by Press – Not Drug Maker – Is Cause for Concern

The fact that GlaxoSmithKline (GSK) has paid $1 billion to settle lawsuits related to Paxil was disclosed by Bloomberg and not the company itself illustrates how lousy financial disclosure rules are in Europe and why drug companies based there cannot be trusted to tell the truth about what is going on with their litigation liabilities and, by extension, the safety of their drugs.

US Kids Represent Psychiatric Drug Goldmine

Prescriptions for psychiatric drugs increased 50 percent with children in the US, and 73 percent among adults, from 1996 to 2006, according to a study in the May/June 2009 issue of the journal Health Affairs. The CIA “World Factbook” estimate the world population to be about 6.8 billion and the US population to be a mere 307 million. In an April 2008 report, the market research firm Datamonitor reported that the “US dominates the ADHD market with a 94 percent market share.”